The bill amends the Rhode Island Medicaid Reform Act of 2008 by introducing a new section that mandates Medicaid coverage for fertility diagnostic care, standard fertility preservation services, and fertility treatment beginning January 1, 2026. This coverage includes:

1. Any medically necessary ovulation-enhancing drugs and medical services related to prescribing and monitoring their use intended to treat infertility and establish a pregnancy that results in a live birth.
2. At least three cycles of ovulation-enhancing medication treatment.
3. Intrauterine insemination.
4. Coverage for in-vitro fertilization and embryo transfer if ovulation-enhancing medication treatment, administered with the intention to prepare for intrauterine insemination, results in an ovulation response that contraindicates intrauterine insemination, as recommended by the treating physician.

The bill specifies that coverage must be provided without discrimination based on age, ancestry, disability, domestic partner status, gender, gender identity or expression, genetic information, marital status, national origin, race, religion, sex, or sexual orientation.

Additionally, the Department of Health is required to submit a report to the General Assembly by January 1, 2026, after consulting with the Centers for Medicare and Medicaid Services. This report will address whether in-vitro fertilization is a medically reasonable and necessary procedure under federal law, potential methods for covering in-vitro fertilization as a medical assistance benefit for both fee-for-service and managed care organizations, including any applicable waiver authorities, and the funding required for such coverage.

The bill defines key terms related to fertility care, including "fertility diagnostic care," "fertility treatment," "infertility," "intrauterine insemination," and "standard fertility preservation services," ensuring clarity in the services covered under the new mandate. The act will take effect upon passage.